1 Report Prologue
2 Market Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
2.3 Market Structure
3 Research Methodology
3.1 Research Process
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
3.5 Forecast Model
4 Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
5 Market Factor Analysis
5.1 Value/Supply Chain Analysis
5.2 Porter's 5 Forces Analysis
6 Global Krabbe Disease Treatment Market, By Treatment Types (USD Million)
6.1 Introduction
6.2 Historical Market Growth
6.3 Market Size By Treatment Types
6.3.1 anticonvulsant medication
6.3.2 physical therapy
6.3.3 muscle relaxer drugs
6.3.4 bone marrow transplantation
6.3.5 hematopoietic stem cell transplant (HSCT)
6.3.6 Others
7 Global Krabbe Disease Treatment Market, By End Users (USD Million)
7.1 Introduction
7.2 Historical Market Growth
7.3 Market Size By End Users
7.3.1 Hospitals and clinics
7.3.2 research centers
7.3.3 laboratories
7.3.4 Others
8 Global Krabbe Disease Treatment Market, By Region
8.1 Introduction
8.2 Incidence of Krabbe Disease Treatment Market By Region
8.3 Market Size By Region
8.3.1 North America
8.3.1.1 US
8.3.1.2 Canada
8.3.2 Europe
8.3.3.1 Western Europe
8.3.2.1.1 Germany
8.3.2.1.2 France
8.3.2.1.3 UK
8.3.2.1.4 Italy
8.3.2.1.5 Spain
8.3.2.1.6 Restof Western Europe
8.3.3 Asia-Pacific
8.3.3.1 Asia
8.3.3.1.1 Japan
8.3.3.1.2 China
8.3.3.1.3 India
8.3.3.1.4 Republic of Korea
8.3.3.1.5 Rest of Asia
8.3.3.2 Pacific
8.3.4 Middle East & Africa
9 Company Landscape
9.1 Introduction: Key Players
9.2 Market Share Analysis
9.3 Key Development & Strategies
10 Company Profiles
10.1 Abbott Laboratories
10.1.1 Company Overview
10.1.2 Product/Business Segment Overview
10.1.3 Financial Updates
10.1.4 Key Developments
10.2 Teva Pharmaceutical Industries Ltd
10.2.1 Company Overview
10.2.2 Product/Business Segment Overview
10.2.3 Financial Updates
10.2.4 Key Developments
10.3 GlaxoSmithKline
10.3.1 Company Overview
10.3.2 Product/Business Segment Overview
10.3.3 Financial Updates
10.3.4 Key Developments
10.4 Johnson & Johnson
10.4.1 Company Overview
10.4.2 Product/Business Segment Overview
10.4.3 Financial Updates
10.4.4 Key Developments
10.5 Novartis AG
10.5.1 Company Overview
10.5.2 Product/Business Segment Overview
10.5.3 Financial Updates
10.5.4 Key Developments
10.6 Pfizer
10.6.1 Company Overview
10.6.2 Product/Business Segment Overview
10.6.3 Financial Updates
10.6.4 Key Developments
10.7 Sanofi-Aventis SA
10.7.1 Company Overview
10.7.2 Product/Business Segment Overview
10.7.3 Financial Updates
10.7.4 Key Developments
10.8 Shire
10.8.1 Company Overview
10.8.2 Product/Business Segment Overview
10.8.3 Financial Updates
10.8.4 Key Developments
10.8 UCB Pharmaceuticals
10.8.1 Company Overview
10.8.2 Product/Business Segment Overview
10.8.3 Financial Updates
10.8.4 Key Developments
10.9 Others
11 Conclusion
12 Appendix